[Peculiarities of antithrombotic treatment in exacerbation of coronary heart disease and transcutaneous coronary interventions in patients suffering from atrial fibrillation and taking vitamin K antagonists (literature review)].
Iavelov
I S
IS
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D003327:Coronary Disease / Q000188:drug therapy* / Q000628:therapy*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D013923:Thromboembolism / Q000517:prevention & control*; D013997:Time Factors; D014812:Vitamin K / Q000037:antagonists & inhibitors*; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014812:Vitamin K; D014859:Warfarin; D006493:Heparin